Determinants of androgen deprivation therapy use for prostate cancer: Role of the urologist

Journal of the National Cancer Institute

Volumn 98, Issue 12, 2006, Pages 839-845

  Shahinian, Vahakn B ^a,b   Kuo, Yong Fang ^a,b   Freeman, Jean L ^a,b   Goodwin, James S ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST;

AGE; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CLINICAL PROTOCOL; COHORT ANALYSIS; COMORBIDITY; DATA BASE; ETHNOLOGY; GEOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PATIENT CARE; PHYSICIAN ATTITUDE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SOCIOECONOMICS; UROLOGY;

AGED; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; EVIDENCE-BASED MEDICINE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIAN'S ROLE; PRESCRIPTIONS, DRUG; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SEER PROGRAM; TIME FACTORS; UROLOGY;

EID: 33745258787     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj230     Document Type: Article

References (44)

1. Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology 2002;60(Suppl 3A):7-12.
2. Shahinian VB, Kuo Y-F, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for localized prostate cancer. Cancer 2005;103:1615-24.
3. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prosaic carcinoma. N Engl J Med 1989;321:419-24.
4. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff R-O, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002;360:103-8.
5. Chodak GW, Keane T, Klotz L, The Hormone Therapy Study Group. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 2002;60:201-8.
6. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003;95:981-9.
7. Holzbeierlein JM, McLaughlin MD, Thrasher JB. Complications of androgen deprivation therapy for prostate cancer. Curr Opin Urol 2004;14:177-83.
8. Part B Physician/Supplier National Data, CY 2003. Top 200 level II health care common procedure coding system codes. Available at: http://www.cms.hhs.gov/MedicareFeeforSvcPartsAB/Downloads/ LEVEL2Charg03.pdf. [Last accessed: March 22, 2006.]
9. Wennberg JE, Barnes BA, Zubkoff M. Professional uncertainty and the problem of supplier-induced demand. Soc Sci Med 1982;16:811-24.
10. Wennberg J, Gittelsohn A. Variations in medical care among small areas. Sci Am 1982;246:120-34.
11. Hofer TP, Hayward RA, Greenfield S, Wagner EH, Kaplan SH, Manning WG. The unreliability of individual physician "report cards" for assessing the costs and quality of care of a chronic disease. JAMA 1999;281:2098-105.
12. Sixma HJ, Spreeuwenberg PM, van der Pasch MA. Patient satisfaction with the general practitioner: A two-level analysis. Med Care 1998;36:212-29.
13. Cowen ME, Strawderman RL. Quantifying the physician contribution to managed care pharmacy expenses: A random effects approach. Med Care 2002;40:650-61.
14. Beaulieu M-D, Blais R, Jacques A, Battista RN, Lebeau R, Brophy J. Are patients suffering from stable angina receiving optimal medical treatment? QJM 2001;94:301-8.
15. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993;31:732-48.
16. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care 2002;40(suppl IV):3-18.
17. Baldwin L-M, Adamache E, Klabunde CN, Kenward K, Dahlman C, Warren JL. Linking physician characteristics and medicare claims data: Issues in data availability, quality and measurement. Med Care 2002;40(suppl IV):82-95.
18. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, et al. Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis. Ann Intern Med 2000;132:566-77.
19. Clinical Practice Guidelines in Oncology. Prostate Cancer. The National Comprehensive Cancer Network version 1.2004.
20. Pilepich MV, Caplan R, Byhardt RW, CA, Gallagher MJ, Mesic JB, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997;15:1013-21.
21. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff R-O, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
22. Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-64.
23. Fritz A, Ries L, editors. SEER extent of disease-1988: Codes and coding instructions. 3rd ed. Bethesda (MD): U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health; 1998.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-83.
25. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258-67.
26. Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 2002;40(8 Suppl):IV-55-61.
27. Nagelkerke NJD. A note on a general definition of the coefficient of determination. Biometrika 1991;78:691-2.
28. Raudenbush SW, Bryk AS. Hierarchical linear models: Applications and data analysis methods. 2nd ed. Thousand Oaks (CA): Sage; 2002.
29. Leyland AH, Goldstein H, editors. Multilevel modeling of health statistics. West Sussex (England): John Wiley and Sons, Ltd.; 2001.
30. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS system for mixed models. 5th ed. Cary (NC): SAS Institute; 2002.
31. Snijders T, Bosker R. Multi-level analysis. Thousand Oaks (CA): Sage; 1999.
32. Goldstein H, Browne W, Rasbash J. Partitioning variation in multilevel models. Understanding Statistics 2002;1:223-32.
33. Orav JE, Wright EA, Palmer HR, Hargraves LJ. Issues of variability and bias affecting multisite measurement of quality of care. Med Care 1996; 34(9 Suppl):SS87-101.
34. Gee WF, Holtgrewe HL, Albertsen PC, Litwin MS, Manyak MJ, O'Leary MP, et al. Practice trends in the diagnosis and management of prostate cancer in the United States. J Urol 1995;154:207-8.
35. General Accounting Office Report. Medicare: Payments for covered outpatient drugs exceed providers' costs. GAO-01-1118. September 21, 2001.
36. Wasson JH, Fowler FJ, Barry MJ. Androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era: A national survey of urologist beliefs and practices. J Urol 1998;159:1993-6.
37. Talcott JA. Androgen deprivation as primary treatment for early prostate cancer: Should we "just do something'"? J Natl Cancer Inst 2002;94: 407-9.
38. Komaromy M, Lurie N, Osmond D, Vranizan K, Keane D, Bindman AB. Physician practice style and rates of hospitalization for chronic medical conditions. Med Care 1996;34:494-609.
39. Westert GP, Groenewegen PP. Medical practice variations: Changing the theoretical approach. Scand J Public Health 1999;27:173-80.
40. Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS. Risk of the "Androgen Deprivation Syndrome" in men receiving androgen deprivation for prostate cancer. Arch Int Med 2006;166:465-71.
41. Surveillance, Epidemiology, and End Results (SEER). Available at: http://www.seer.cancer.gov. Program Public-Use Data (1973-1999), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2002, based on the November 2001 submission. [Last accessed: May 14, 2006.]
42. Riley GF, Potosky AL, Klabunde CN, Warren JL, Ballard-Barbash R. Stage at diagnosis and treatment patterns among older women with breast cancer. an HMO and fee-for-service comparison. JAMA 1999;281:720-6.
43. Bravo G, Potvin L. Estimating the reliability of continuous measures with Cronbach's Alpha or the intraclass correlation coefficient: Toward the integration of two traditions. J Clin Epidemiol 1991;44:381-90.
44. McDowell I, Newell C. Measuring health: A guide to rating scales and questionnaires. 2nd ed. New York (NY): Oxford University Press; 1996.